From OrbiMed Asia
Vivimed Labs has signed definitive agreements and received funds to facilitate additional investment of USD 7.5 million (follow on of USD 42.5 million invested in September 2017) by OrbiMed Asia into the Company's subsidiary Vivimed Labs (Mascarene), the holding entitiy of the Company's API business.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
